Clinical Trial Update: Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy [Phase 2]

View source ↗

Summary

Phase 2 study update on quantification tools for a novel tau PET marker, 18F-PI-2620, in progressive supranuclear palsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Progressive Supranuclear Palsy

Drugs mentioned

• [18F]PI-2620 (PI-2620)

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Parkinson Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING